Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397223 · ClinicalTrials.gov registry record · Phase 1
A Study of Modified mRNA Vaccines in Healthy Adults
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 308
- Enrollment target
NCT05397223: Completed Phase 1 study, sponsored by ModernaTX.
NCT05397223 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 308 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (413% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05397223, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 308 participants
- Enrollment target
Study Summary
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
Interventions
- BIOLOGICAL mRNA-1273
- BIOLOGICAL mRNA-1647
- BIOLOGICAL mRNA-1345
- BIOLOGICAL mRNA-1010
- BIOLOGICAL FLUAD®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2022-05-24 |
| Est. Completion | 2026-02-27 |
| Phase | Phase 1 |
What the finished NCT05397223 record still lists
NCT05397223 is an interventional study that assigns participants to a tested intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (413% higher).
The record links to 0 conditions, and to 5 interventions - of which mRNA-1273 is the first listed.
NCT05397223 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05397223 about?
NCT05397223 is a clinical study titled "A Study of Modified mRNA Vaccines in Healthy Adults". The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
What is the current status of trial NCT05397223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 308 participants. The study started on 2022-05-24. Estimated completion is 2026-02-27.
What interventions are being tested in trial NCT05397223?
The interventions under investigation include: mRNA-1273 (BIOLOGICAL), mRNA-1647 (BIOLOGICAL), mRNA-1345 (BIOLOGICAL), mRNA-1010 (BIOLOGICAL), FLUAD® (BIOLOGICAL).
Who is sponsoring clinical trial NCT05397223?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05397223's enrollment target sits among peer trials
308 122nd of 2000 higher than 1,877 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI